Emmaus Life Sciences, Inc.

OTCPK:EMMA Stock Report

Market Cap: US$890.9k

Emmaus Life Sciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:EMMA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 Sep 24BuyUS$800Seah LimIndividual20,000US$0.04
29 Feb 24BuyUS$12,894Willis LeeIndividual100,200US$0.13
28 Feb 24BuyUS$1,800Willis LeeIndividual15,000US$0.12

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of EMMA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies92,7940.145%
Public Companies4,147,4916.49%
Individual Insiders23,637,10137%
General Public35,988,18556.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.3%.

Top Shareholders

Top 9 shareholders own 43.65% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19%
Yutaka Niihara
12,110,057US$168.9k0%no data
9.46%
Wei Peu Zen
6,039,031US$84.2k0%no data
7.21%
Seah Lim
4,606,626US$64.3k0.44%no data
6.49%
TELCON RF PHARMACEUTICAL. Inc.
4,147,491US$57.9k0%no data
1.25%
Willis Lee
795,718US$11.1k0%no data
0.15%
Hope International Hospice, Inc.
92,794US$1.3k0%no data
0.11%
Yasushi Nagasaki
67,102US$936.10%no data
0.028%
Charles Stark
18,182US$253.60%no data
0.0006%
George Sekulich
385US$5.30%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:08
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Emmaus Life Sciences, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bradley SorensenZacks Small-Cap Research